The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
|Videos|August 3, 2011
Dr. Hoos Discusses Patients Eligible to Receive Ipilimumab
Author(s)Axel Hoos, MD, PhD
Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab
Advertisement
Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb, discusses that the ipilimumab (Yervoy) label is very broad and includes both pretreated and untreated metastatic melanoma. No subset of patients has been identified that will not benefit from the drug. Evaluating prognostic information reveals that survival benefits has been found in all groups.
Advertisement
Related to this article
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
Advertisement
Advertisement
Trending on OncLive
1
Dr Fradley on Real-World Atrial Fibrillation and Cardiovascular Outcomes in CLL
2
Poll Results Highlight Breast Cancer Abstracts of Interest at ESMO 2026
3
FDA Grants Fast Track Designation to Opamtistomig for Advanced Biliary Tract Cancer
4
Dr Hansen on the Integration of CAR T-Cell Therapy Into Earlier Myeloma Treatment Lines
5